Literature DB >> 11339361

HIV vaccine development at Duke University Medical Center.

B F Haynes1, H X Liao, H F Staats, M S Alam, K J Weinhold, D C Montefiori.   

Abstract

With the AIDS epidemic continuing to spread throughout the world, development of a safe, practical, and effective HIV vaccine is a national priority. HIV vaccine research efforts are currently targeted towards design of HIV immunogens that induce both cellular and humoral immunity. This brief review summarizes ongoing work at the Duke University School of Medicine on HIV vaccine development.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11339361     DOI： 10.1385/ir:22:2-3:263

Source DB:  PubMed          Journal:  Immunol Res        ISSN： 0257-277X            Impact factor:   2.829


  26 in total

1.  Induction of antibodies in guinea pigs and rhesus monkeys against the human immunodeficiency virus type 1 envelope: neutralization of nonpathogenic and pathogenic primary isolate simian/human immunodeficiency virus strains.

Authors:  H X Liao; B Etemad-Moghadam; D C Montefiori; Y Sun; J Sodroski; R M Scearce; R W Doms; J R Thomasch; S Robinson; N L Letvin; B F Haynes
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

2.  Priming of anti-human immunodeficiency virus (HIV) CD8+ cytotoxic T cells in vivo by carrier-free HIV synthetic peptides.

Authors:  M K Hart; K J Weinhold; R M Scearce; E M Washburn; C A Clark; T J Palker; B F Haynes
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-01       Impact factor: 11.205

Review 3.  Dominance and crypticity of T cell antigenic determinants.

Authors:  E E Sercarz; P V Lehmann; A Ametani; G Benichou; A Miller; K Moudgil
Journal:  Annu Rev Immunol       Date:  1993       Impact factor: 28.527

4.  Superdominance among immunodominant H-2Kb-restricted epitopes and reversal by dendritic cell-mediated antigen delivery.

Authors:  J K Sandberg; P Grufman; E Z Wolpert; L Franksson; B J Chambers; K Kärre
Journal:  J Immunol       Date:  1998-04-01       Impact factor: 5.422

5.  Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate envelope.

Authors:  N L Letvin; S Robinson; D Rohne; M K Axthelm; J W Fanton; M Bilska; T J Palker; H X Liao; B F Haynes; D C Montefiori
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

6.  NMR-derived solution conformations of a hybrid synthetic peptide containing multiple epitopes of envelope protein gp120 from the RF strain of human immunodeficiency virus.

Authors:  R de Lorimier; M A Moody; B F Haynes; L D Spicer
Journal:  Biochemistry       Date:  1994-03-01       Impact factor: 3.162

7.  Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120.

Authors:  J R Rusche; K Javaherian; C McDanal; J Petro; D L Lynn; R Grimaila; A Langlois; R C Gallo; L O Arthur; P J Fischinger
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

8.  Restricted neutralization of divergent human T-lymphotropic virus type III isolates by antibodies to the major envelope glycoprotein.

Authors:  T J Matthews; A J Langlois; W G Robey; N T Chang; R C Gallo; P J Fischinger; D P Bolognesi
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

9.  Conformational preferences of a chimeric peptide HIV-1 immunogen from the C4-V3 domains of gp120 envelope protein of HIV-1 CAN0A based on solution NMR: comparison to a related immunogenic peptide from HIV-1 RF.

Authors:  H M Vu; R de Lorimier; M A Moody; B F Haynes; L D Spicer
Journal:  Biochemistry       Date:  1996-04-23       Impact factor: 3.162

10.  Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS.

Authors:  R C Gallo; S Z Salahuddin; M Popovic; G M Shearer; M Kaplan; B F Haynes; T J Palker; R Redfield; J Oleske; B Safai
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.